Viridian Therapeutics, Inc. VRDN Change in Accrued Liabilities
Change in Accrued Liabilities at other companies
Other financials
Where this comes from
Reported directly by Viridian Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:IncreaseDecreaseInAccruedLiabilities.
The official record: Viridian Therapeutics, Inc.’s 10-Q, filed May 5, 2026, on SEC EDGAR. View the filing →
Ask your AI about Viridian Therapeutics, Inc.'s change in accrued liabilities.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Viridian Therapeutics, Inc.'s change in accrued liabilities?
- Viridian Therapeutics, Inc. (VRDN) reported change in accrued liabilities of -$23.69M in Q1 2026.
- How has Viridian Therapeutics, Inc.'s change in accrued liabilities changed year-over-year?
- Viridian Therapeutics, Inc.'s change in accrued liabilities decreased by 48.9% year-over-year, from -$15.91M to -$23.69M.
- What does change in accrued liabilities mean?
- Change in accrued expenses and other current liabilities, reflecting timing differences between expense recognition and cash payment.